Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
Akoya Biosciences, Inc. (AKYA), known as The Spatial Biology Company®, generates news that spans technology developments, collaborations, financial reporting, and corporate transactions. Company announcements emphasize its single-cell imaging and spatial proteomics platforms, which are used to phenotype cells with spatial context and study how they organize and interact in disease. News items often describe how Akoya’s PhenoCode™ Panels, PhenoCycler®, Phenor® Fusion, and Phenor HT instruments are applied across discovery, translational, and clinical research.
Investors and researchers following AKYA-related news will find updates on spatial biology and proteomics initiatives, including large-scale projects and partnerships. Recent releases highlight collaborations such as the Cancer Grand Challenges-funded study using PhenoCycler-Fusion, the SUPER study with the Singapore Translational Cancer Consortium leveraging the IO60 panel to investigate PD-1 immunotherapy response, and the Enable Medicine Pan-Cancer Atlas built on Akoya’s PhenoCycler-Fusion and IO60 technologies. These stories illustrate how Akoya’s platforms are integrated into biomarker discovery, drug development, and precision oncology efforts.
News coverage has also included financial results and operational updates, such as quarterly revenue composition, changes in operating expenses, and growth in the installed base of instruments and publications citing Akoya’s technology. In addition, corporate and capital markets news has been prominent, particularly the Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and subsequent shareholder and activist responses to that transaction.
Following the completion of the merger on July 8, 2025, Akoya became a wholly owned subsidiary of Quanterix, and its common stock was removed from listing on Nasdaq. The AKYA news stream therefore serves as a historical archive of Akoya’s activities as an independent public company, covering its evolution in spatial biology, its collaborations, and the steps leading to its acquisition by Quanterix.
Akoya Biosciences (Nasdaq: AKYA) recently showcased its latest innovations in spatial biology at the second annual Spatial Day event. The company introduced ready-to-use PhenoCode panels, enhancements to the PhenoCycler-Fusion platform to double throughput, and expanded software partnerships for data analysis. Akoya's advancements aim to simplify and accelerate the discovery of spatial signatures, improving patient outcomes in precision medicine. The new products and partnerships reflect Akoya's commitment to enhancing research capabilities for clinical and translational scientists.
Akoya Biosciences (Nasdaq: AKYA) reported a strong performance for Q3 2022, with revenues of $18.9 million, marking a 40% year-over-year increase. Product revenue rose to $14.4 million, up 32%, driven by a 67% increase in instrument sales with 55 units sold. The installed base has reached 863 instruments. Year-to-date revenue is $53.6 million, up 38%. Gross profit for the quarter was $10.9 million, maintaining a 58% margin. The company has raised its full-year revenue guidance to $73-75 million due to positive growth trends and strong market execution.
Akoya Biosciences (Nasdaq: AKYA) has launched PhenoCode™ Signature Panels for high-throughput spatial biomarker discovery on PhenoImager® platforms. These customizable multiplex panels enable phenotyping of the tumor microenvironment and immune status, streamlining biomarker validation for immuno-oncology applications. This development reflects Akoya's commitment to enhancing predictive tissue-based biomarker solutions, with a focus on accelerating research and clinical trials. Akoya will present their findings at the SITC 37th Annual Meeting in Boston from November 8-12, 2022.
Akoya Biosciences (Nasdaq: AKYA), known as The Spatial Biology Company®, announced its participation in three investor conferences. These include a fireside chat at the Stephens Annual Investment Conference on November 16, a panel at the Canaccord Genuity Annual MedTech Forum on November 17, and another fireside chat at the Piper-Sandler Annual Healthcare Conference on December 1. Live webcasts will be accessible on Akoya's website.
Akoya Biosciences, Inc. (Nasdaq: AKYA) will announce its Q3 2022 financial results on November 7, 2022, after market close. Following the announcement, management will host a conference call at 5:00 p.m. ET to discuss the results. Interested investors are encouraged to register in advance for the call. Akoya specializes in spatial biology, offering innovative solutions for single-cell imaging and spatial phenotyping, aimed at enhancing understanding of biology and health.
Akoya Biosciences (Nasdaq: AKYA) will participate in four upcoming investor conferences, showcasing its advancements in spatial biology.
The events include:
- H.C. Wainwright 24th Annual Global Investment Conference - September 12 at 11:30 AM ET
- Morgan Stanley 20th Annual Global Healthcare Conference - September 14 at 8:35 AM ET
- Capital One Spatial Biology & Proteomics Summit - September 28 at 10:15 AM and 1:00 PM ET
- Bank of America Healthcare Innovation Forum - September 29 at 11 AM ET
Webcasts of the events will be available on Akoya's website.
Akoya Biosciences (Nasdaq: AKYA) reported a strong Q2 2022 with revenue reaching $17.9 million, a 37% year-over-year growth. Product revenue increased by 33% to $14.2 million, while services and other revenue surged 54% to $3.7 million. The company sold 60 instruments, marking a 94% increase in sales. Akoya also raised its FY 2022 revenue guidance to $71-74 million, supported by $88 million in cash and equivalents. The company expanded its credit facility by $20 million to enhance liquidity.
Akoya Biosciences (Nasdaq: AKYA), The Spatial Biology Company®, will participate in two investor conferences in August 2022. The first is the UBS Genomics 2.0 and MedTech Innovation Conference, featuring a fireside chat with CEO Brian McKelligon and CBO Niro Ramachandran on August 9th at 1:00 PM PT. The second event, the Canaccord Growth Conference, includes a panel discussion on spatial omics with CEO McKelligon on August 10th at 12:00 PM ET. Both sessions will be broadcast live and available for replay.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has announced that it will release its second-quarter financial results on August 8, 2022, after market close. A conference call for investors will take place at 5:00 p.m. ET to discuss these results. Investors can register for the call online and access a webcast on the company’s investor relations website. Akoya specializes in spatial phenotyping, providing advanced single-cell imaging solutions to enhance research in biology and health.
Akoya Biosciences and Acrivon Therapeutics announced a partnership to co-develop the innovative OncoSignature test, designed to identify cancer patients most likely to respond to ACR-368, a targeted oncology agent in Phase 2 trials. ACR-368 aims to treat ovarian, endometrial, and urothelial cancers, with promising results in platinum-resistant ovarian cancer. The OncoSignature will utilize Akoya’s PhenoImager technology for patient selection to enhance treatment outcomes, pending ACR-368's approval.
FAQ
What is the current stock price of Akoya Biosciences (AKYA)?
What is the market cap of Akoya Biosciences (AKYA)?
